(Albany, US) DelveInsight has launched a new report on Allergic Rhino-Conjunctivitis Pipeline
“Allergic Rhino-Conjunctivitis Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Allergic Rhino-Conjunctivitis market. A detailed picture of the Allergic Rhino-Conjunctivitis pipeline landscape is provided, which includes the disease overview and Allergic Rhino-Conjunctivitis treatment guidelines. The assessment part of the report embraces in-depth Allergic Rhino-Conjunctivitis commercial assessment and clinical assessment of the Allergic Rhino-Conjunctivitis pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Allergic Rhino-Conjunctivitis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Allergic Rhinoconjunctivitis (ARC), which is caused by an allergen, refers to nose and eye problems that occur at least once a week. When only the nose is affected, it is called allergic rhinitis (AR). It is also known as hay fever, “sinus” or “sensitive nose”. When only the eyes are affected, it is called allergic conjunctivitis. The disease is triggered by exposure to seasonal and/or perennial allergens and, depending on the nature of the allergenic triggers and patterns of exposure, symptoms may be persistent or intermittent.
Request for free sample page:- https://www.delveinsight.com/sample-request/allergic-rhino-conjunctivitis-pipeline-insight
Allergic Rhino-Conjunctivitis Pipeline
The development of new drugs for ARC is analyzed by highlighting the recent insights into the pathophysiological mechanisms of the disease. The major aim of development of drugs for ARC is to have agents able to prevent the inflammatory effects of the interaction between the allergen and the specific IgE antibodies on mast cell surface.
Some of the key players including LOFARMA S.P.A, Emergo Therapeutics, FAES Farma, and others are developing drugs for the treatment of Allergic Rhinoconjunctivitis. Lais allergoid tablets contain allergens that are modified by carbamylation. Due to their modified chemical structure, they are suitable for sublingual immunotherapy (SLIT). Based on their small molecule size of 12 to 40 kDa, they can be easily absorbed via the oral mucosa.
Norketotifen is the principal active metabolite of ketotifen, a known antagonist of the histamine H1 receptor and mast stabilizer. Ketotifen has been approved in over 95 countries worldwide, including the US and Europe, for the treatment of asthma and/or allergic conditions in children and adults. Norketotifen, however, has not been approved anywhere for any indication. Emergo has already completed all the scientific and commercial due diligence to reassure investors of the market potential for norketotifen in this lead indication. Recently the company completed the phase IIb clinical trial for ARC. Bilastine (a piperidine derivative), is a novel potent H1 antihistamine. It is at least as potent as cetirizine or fexofenadine in in vitro studies. In animal studies it demonstrates dose-dependent antihistaminic and anti-allergic effects. In humans its metabolism is not affected by age, gender or renal function but may be affected by co-administration of P glycoprotein inhibitors.
Marketed drug included in the report
- Itulazax: ALK-Abelló A/S
Emerging drugs included in the report
- Norketotifen: Emergo Therapeutics
- LAIS Grass pollen tablets: LOFARMA S.P.A
- Bilastine: FAES Farma
Allergic Rhino-Conjunctivitis Report Scope
- The Allergic Rhino-Conjunctivitis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Allergic Rhino-Conjunctivitis across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Allergic Rhino-Conjunctivitis therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Allergic Rhino-Conjunctivitis research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Allergic Rhino-Conjunctivitis.
Download free sample page:- https://www.delveinsight.com/sample-request/allergic-rhino-conjunctivitis-pipeline-insight
Table of content
1. Report Introduction
2. Allergic Rhino-Conjunctivitis
3. Allergic Rhino-Conjunctivitis Current Treatment Patterns
4. Allergic Rhino-Conjunctivitis – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Allergic Rhino-Conjunctivitis Late Stage Products (Phase-III)
7. Allergic Rhino-Conjunctivitis Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Allergic Rhino-Conjunctivitis Discontinued Products
13. Allergic Rhino-Conjunctivitis Product Profiles
14. Allergic Rhino-Conjunctivitis Key Companies
15. Allergic Rhino-Conjunctivitis Key Products
16. Dormant and Discontinued Products
17. Allergic Rhino-Conjunctivitis Unmet Needs
18. Allergic Rhino-Conjunctivitis Future Perspectives
19. Allergic Rhino-Conjunctivitis Analyst Review
21. Report Methodology
- Allergic Rhino-Conjunctivitis Market Insights, Epidemiology and Market Forecast 2030
- Allergic Rhino-Conjunctivitis Epidemiology Forecast 2030
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions